The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.
 
Maya Kansara
No Relationships to Disclose
 
Frank Po-Yen Lin
No Relationships to Disclose
 
Subotheni Thavaneswaran
Research Funding - AstraZeneca (Inst); Elevation Oncology (Inst); Roche/Genentech (Inst)
 
Christine E Napier
No Relationships to Disclose
 
John P. Grady
No Relationships to Disclose
 
Mandy L. Ballinger
Honoraria - Roche (I)
Research Funding - Amgen (I); AstraZeneca (I); Bayer (I); Elevation Oncology (I); George Clincal (I); Lilly (I); Microba (I); Pfizer (I); Roche (I); Seagen (I); Sun Pharma (I)
Travel, Accommodations, Expenses - Amgen (I)
 
John Simes
Consulting or Advisory Role - FivePhusion (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
David Morgan Thomas
Employment - Australian Unity
Honoraria - Roche
Research Funding - Amgen; AstraZeneca; Bayer; Elevation Oncology; George Clincal (Inst); InterVenn Biosciences; Lilly (Inst); Microba (Inst); Pfizer; Roche; Seagen (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Amgen